Table 1.
Characteristics of trials included in the meta-analysis
| Reference | Design | n | Mean Age (SD) | Ulcer Etiology | Duration, Mean (SD) |
|---|---|---|---|---|---|
| Driver16 | RCT | 72 | PG:56.4 (10.2) CG:57.5 (9.1) |
Diabetic | Not specified |
| Saldalamacchia et al.24 | RCT | 14 | PG:61.1 (9.4) CG:58.1 (7.8) |
Diabetic | Not specified |
| Steed et al.23 | RCT | 13 | PG:58.7 (12.4) CG:54.2 (12.9) |
Diabetic | PG:17.08 (15.87) CG:13 (14.37) (months) |
| Li et al.13 | RCT | 117 | PG:61.4 (13.1) CG:64.1 (9.4) |
Diabetic | PG:30 (55.56) CG:120 (80) (days) |
| Steed et al.31 | RCT | 36 | Not specified | Diabetic | PG/CG:20 (13.75) (months) |
| Ahmed et al.27 | RCT | 56 | PG:49.8 (15.4) CG:43.2 (18.2) |
Diabetic | PG:11.5 (2.8) CG:12.5 (1) (weeks) |
| Holloway et al.25 | RCT | 81 | Not specified | Diabetic | Not specified |
| Friese et al.26 | RCT | 42 | Not specified | Diabetic | Not specified |
| Weed et al.30 | RCT | 26 | PG:67.6 (11.9) CG:57.8 (18.2) |
Mixed: 9 multifactorial, 7 neurotrophic, 5 venous ulcers, 3 traumatic, 1 idiopathic, and 1 pressure ulcer | Not specified |
| Ban et al.33 | RCT | 62 | PG:58 (11) CG:60 (9) |
Diabetic | PG:90 (65.19) CG:60 (42.22) (days) |
| Stacey et al.17 | RCT | 86 | PG:70 (48.89) CG:72 (40.74) |
Venous disease | PG:60 (434.8) CG:69 (523.7) (months) |
| Knighton et al.35 | RCT | 32 | PG:64 (8) CG:62 (10) |
Mixed: 10 venous disease, 9 diabetic, 4 occlusive peripheral vascular disease, and 1 vasculitis | Not specified |
| Anitua et al.34 | RCT | 15 | PG:45 (20) CG:61 (16) |
Mixed: 10 venous disease, 4 pressure sore, and 1 other | PG:68 (61) CG:110 (164) (weeks) |
| Krupski et al.14 | RCT | 26 | PG:66 (5) CG:67 (4.5) |
Mixed: 78% diabetic, 72% occlusive peripheral vascular disease, and 28% venous disease | PG:6.2 (4.4) CG:4.3 (4.1) (months) |
| Senet et al.32 | RCT | 15 | PG:72.3 (31.8) CG:72.3 (24.4) |
Venous disease | PG:50.6 (174.8) CG:70 (71.11) (months) |
| Moneib et al.29 | RCT | 40 | PG:36.4 (10.2) CG:32.5 (7.5) |
Venous disease | Not specified |
| Oliveira et al.28 | RCT | 21 | PG:55 (18) CG:79 (8) |
Venous disease | PG:24 (47.41) CG:21 (78.52) (months) |
| Reference | APRP/HPRP | Interventions | Treatment Duration | Follow-up | Jadad Score |
|---|---|---|---|---|---|
| Driver16 |
APRP |
PRP group: application of APG twice a week. Control group: application of Saline. Co-treatment: the gel was covered with a contact layer dressing. |
Until ulcer healing or for a 12-week period |
24 weeks |
7 |
| Saldalamacchia et al.24 |
APRP |
PRP group: APG once a week plus standard care. Control group: standard care. Co-treatment: self-glucose control. |
Until ulcer healing or for a 5-week period |
5 weeks |
2 |
| Steed et al.23 |
HPRP |
PRP group: application of CT-102 once a week. Control group: application of saline gel. |
Until ulcer healing or for a 20-week period |
20 weeks |
3 |
| Li et al.13 |
APRP |
PRP group: APRP plus standard care every 2 weeks Control group: standard care. Co-treatment: all ulcers were covered with sterile wound dressings, which were changed every 3 days. |
Until ulcer healing or for a 12-week period |
12 weeks |
5 |
| Steed et al.31 |
HPRP |
PRP group: application of CT-102 once per day. Control group: application of saline gauze. |
Until ulcer healing or for a 20-week period |
120 weeks |
3 |
| Ahmed et al.27 |
APRP |
PRP group: application of PG twice a week. Control group: standard care. |
Until ulcer healing or for a 12-week period |
12 weeks |
2 |
| Holloway et al.25 |
HPRP |
PRP group: topical application of CT-102 once daily. Control group: placebo. |
Until ulcer healing or for a 20-week period |
20 weeks |
5 |
| Friese et al.26 |
APRP |
PRP group: application of PRP every 2 weeks. Control group: cleaning, polyurethane foam dressing applied and changed as needed, debridement and off- loading. |
Until ulcer healing or for a 12-week period |
25 weeks |
4 |
| Weed et al.30 |
APRP |
PRP group: autologous platelet lysate. Control group: platelet-poor plasma. Co-treatment: they both combined with collagen for the first 12 weeks of therapy. |
Until ulcer healing or for a 12-week period |
24 weeks |
5 |
| Ban et al.33 |
APRP |
PRP group: APG plus usual care. Control group: usual care. |
Until ulcer healing or for a 12-week period |
12 weeks |
4 |
| Stacey et al.17 |
APRP |
PRP group: autologous platelet-rich lysate. Control group: placebo. Co-treatment: topical application two times a week associated with gauze and pressure dressing. |
Until ulcer healing or for a 36-week period |
36 weeks |
5 |
| Knighton et al.35 |
APRP |
PRP group: application of APRP. Control group: placebo. Co-treatment: debridement before treatment. |
Until ulcer healing or for an 8-week period |
16 weeks |
6 |
| Anitua et al.34 |
APRP |
PRP group: autologous PRGF plus conventional treatment. Control group: conventional treatment. |
Until ulcer healing or for an 8-week period |
8 weeks |
4 |
| Krupski et al.14 |
APRP |
PRP group: application of APRP. Control group: saline. Co-treatment: all ulcers were debridement before treatment, and then were covered by one layer petrolatum-impregnated gauze after treatment. |
Until ulcer healing or for a 12-week period |
12 weeks |
6 |
| Senet et al.32 |
APRP |
PRP group: frozen autologous platelet suspension in saline solution. Control group: saline. Co-treatment: patients received standard topical and pressure treatment, three times per week. |
Until ulcer healing or for a 12-week period |
12 weeks |
5 |
| Moneib et al.29 |
APRP |
PRP group: application of APRP weekly Control group: conservatively by compression using graduated elastic stockings below the knee and dressing using saline and Vaseline gauze weekly |
Until ulcer healing or for a 6-week period |
6 weeks |
3 |
| Oliveira et al.28 | HPRP | PRP group: application of HPRP every 1 week Control group: application of gauze soaked in saline with a second cover of dry gauze and single-layer pressure bandage. |
Until ulcer healing or for a 90-day period | 90 days | 4 |
APG, autologous platelet gel; APRP, autologous platelet-rich plasma; CG, control group; HPRP, homologous platelet-rich plasma; PG: plate-rich plasma group; PRGF, preparation rich in growth factors; PRP, platelet-rich plasma; RCT, randomized controlled trial.